TRAP220/MED1 RNAi Summary
| Specificity |
PPAR binding protein (PPARBP), mRNA
|
| Gene |
MED1
|
Applications/Dilutions
| Application Notes |
This RNAi causes protein knockdown.
|
Packaging, Storage & Formulations
| Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
Notes
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for TRAP220/MED1 RNAi
- Activator-recruited cofactor 205 kDa component
- ARC205
- CRSP1TRIP2
- CRSP200p53 regulatory protein RB18A
- DRIP230
- DRIP230PPAR-binding protein
- MBD4
- MED1
- mediator complex subunit 1DRIP205
- mediator of RNA polymerase II transcription subunit 1
- PBPPPARGBP
- Peroxisome proliferator-activated receptor-binding protein
- PPAR binding protein
- PPARBP
- PPARBPMGC71488
- PPARG binding protein
- PPARGBP
- RB18ATR-interacting protein 2
- Thyroid hormone receptor-associated protein complex 220 kDa component
- thyroid hormone receptor-associated protein complex component TRAP220
- thyroid receptor interacting protein 2
- Thyroid receptor-interacting protein 2
- TRAP220
- TRAP220TRIP-2
- TRIP2
- vitamin D receptor-interacting protein 230 kD
- Vitamin D receptor-interacting protein complex component DRIP205
Background
Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.
